LDL - How low can you go? Terry Jacobsen, MD

Slides:



Advertisements
Similar presentations
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Advertisements

Treat Everyone to an LDL-C of 70mg/dl? Daniel Edmundowicz, MS, MD, FACC Associate Professor Of Medicine Director, Preventive Cardiology UPMC Cardiovascular.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels Results of AFCAPS/TexCAPS John R. Downs, Michael.
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.
Biases in identifying risk factor thresholds: A new look at the "lower- is-better" controversy for cholesterol, blood pressure and other risk factors Ian.
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Modern Management of Cholesterol in the High-Risk Patient.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
B-1 Pravastatin-Aspirin Combination René Belder, M.D. Executive Director Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute Bristol-Myers.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:
Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med.
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
Baseline characteristics of HPS participants by prior cerebrovascular disease.
Date of download: 9/19/2016 From: Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem Ann.
NICE –CG 181 Continuum of CVD Risk and its treatment
The ALERT Trial.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Title slide.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
The Importance of Adequately Powered Studies
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Establishing the benefit of statins in low-to-moderate—risk primary prevention: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) 
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
The Latest Lipid Guidelines:
HDL cholesterol and cardiovascular risk
Classification of total cholesterol levels
TNT: Baseline and final LDL cholesterol levels
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report  Scott M. Grundy, Hidenori.
Section II: Lipid management
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Section 7: Aggressive vs moderate approach to lipid lowering
Section 9: Continuum of care: Summary and timeline
This series of slides highlights a report based on a presentation at the Late-Breaking Trial Sessions of the 2005 American Heart Association Scientific.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
How to Optimize Cholesterol Management in High-Risk CV Patients
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Potential mechanisms whereby statins may reduce the risk of stroke
Goals & Guidelines A summary of international guidelines for CHD
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk  Terry.
Delahoy PJ, et al. Clin Ther 2009;31:236-44
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Section 6: Update on lipid treatment guidelines
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

LDL - How low can you go? Terry Jacobsen, MD Director, Office of Health Promotion and Disease Prevention Emory University Atlanta, GA Anthony Gotto, MD Dean, Cornell University Medical College New York City, NY

LDL-How low can you go? Is lower really better? "The Lower the Better" in Hypercholesterolemia Therapy: A Reliable Clinical Guideline? 0:52.3 Jacobson TA. Ann Intern Med 2000 ; 133:549-554

LDL-How low can you go? Epidemiology Studies show curvilinear relationship PROCAM: Prospective Cardiovascular Munster Study MRFIT: Multiple Risk Factor Intervention Trial The mean lipid level for a CHD survivor is between 120 and 140 mg/dL. A “diminishing returns model” of benefit as lipid levels are lowered. 2:25

LDL-How low can you go? Secondary prevention trials CARE: Cholesterol and Recurrent Events trial No cardioprotective benefit in reducing LDL from 124 mg/dL to 71 mg/dL LIPID: Long-Term Intervention with Pravastatin in Ischaemic Disease study Showed only a 16% relative risk reduction in patients with LDL below 135 mg/dL 4:25

LDL-How low can you go? 4S trial Reductions in relative risk were independent of baseline LDL cholesterol levels: -35% in patients with LDL <169 mg/dL -36% in patients with LDL >206 mg/dL 6:30.5

LDL-How low can you go? Post-CABG trial Patients with saphenous vein grafts randomized to: moderate therapy (LDL <130) aggressive therapy (LDL <100) 4 year results: no significant difference in non-fatal MI or cardiovascular death 7:11.0

LDL-How low can you go? Primary prevention WOSCOPS AFCAPS/TexCAPS (West Of Scotland COronary Prevention Study) AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) No evidence that the higher dose led to greater reduction of events. 7:11.0

LDL-How low can you go? More isn’t better “The pharmacoeconomics also mitigate that maybe we can’t afford to get patients as low as possible. That maybe we need to focus in on other risk factors after we do drive LDL levels to goal.” Terry Jacobsen, MD Director, Office of Health Promotion and Disease Prevention Emory University Atlanta, GA 8:19.5

LDL-How low can you go? “2 to 1” The Lipid Research Clinic (LRC) trial established the “2 to 1” relation between cholesterol reduction and risk reduction. AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) did not show a linear relationship, but also did not show a threshold. 9:38.5

LDL-How low can you go? Hazards of subgroup analyses Subgroup analyses are hypothesis generating, not conclusive. What is the real premise of the trial? Who benefited from therapy? AFCAPS/TexCAPS: LDL>130 w/HDL<50 CARE: LDL >160 w/established CAD 9:38.5

LDL-How low can you go? Two questions If you start at LDL >120 or 200, should you be more aggressive? 2) With LDL 100-130, are you getting benefit by being more aggressive? Must wait for TNT, SEARCH, OXFORD trials 9:38.5

LDL-How low can you go? Goals aren’t everything LRC study showed no incremental reduction after 30% LDL reduction. Many trials didn’t reach NCEP goals, but did show benefit. Goals are important for populations, but advocating beyond them is premature. 9:38.5

LDL-How low can you go? Other factors Are there adverse consequences of a large LDL reduction? Are there dangers of hemorrhagic stroke? Are there other properties of statin therapy? Need to look at other risk factors as aggressively. 9:38.5

LDL-How low can you go? Treating to target Some patients’ LDL simply can’t be lowered to an acceptable target level. You can see benefit without reaching target, but would you see more if LDL were lower? We may never be able to completely answer the question. 9:38.5